H.C. Wainwright analyst Andres Maldonado assumed coverage of Verastem (VSTM) with a Buy rating and $18 price target The firm views VS-7375 as one of the most underappreciated aspects of the Verastem story. It sees emerging evidence that the KRAS franchise may “ultimately represent the larger long-term value driver.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up
- Verastem updates oncology strategy in new corporate presentation
- Verastem Shifts Focus to KRAS G12D and Pancreatic Programs
- Verastem ending RAMP 203 study doesn’t impact thesis, says Guggenheim
- Closing Bell Movers: Ekso Bionicis surges after Applied Digital deal